An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System Carine Raquel Blatt, PhD, Noemia Liege Maria da Cunha Bernardo, MSc, Junior Andre Rosa, MSc, Fabiola Bagatini, MSc, Rodrigo Fernandes Alexandre, MSc, Giacomo Balbinotto Neto, PhD, Uwe Siebert, Mareni Rocha Farias, PhD Value in Health Regional Issues Volume 1, Issue 2, Pages 129-135 (December 2012) DOI: 10.1016/j.vhri.2012.10.001 Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 1 Percentage of total direct cost for treatment of hepatitis C with interferon alpha plus ribavirin and peginterferon alpha 2a 180 μg plus ribavirin. IFN, interferon alpha; PEG, peginterferon alpha; RBV, ribavirin. Value in Health Regional Issues 2012 1, 129-135DOI: (10.1016/j.vhri.2012.10.001) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions